Advertisement

Urological Research

, Volume 22, Issue 4, pp 239–245 | Cite as

Effects of sequential intravesical administration of mitomycin C and bacillus Calmette-Guérin on the immune response in the guinea pig bladder

  • L. T. M. Balemans
  • P. D. J. Vegt
  • P. A. Steerenberg
  • E. C. De Boer
  • A. Van Swaaij
  • R. E. M. De Vries
  • A. P. M. Van Der Meijden
  • W. Den Otter
Original Paper

Abstract

It has been suggested that intravesical treatment with mitomycin C (MMC) before instillation of bacillus Calmette-Guérin (BCG) improves the antitumor activity of BCG in human bladder cancer. Therefore, we studied the immunological effects of sequential intravesical treatment with MMC and BCG in the guinea pig. Four weekly intravesical instillations with MMC preceded six weekly intravesical BCG instillations. The delayed-type hypersensitivity (DTH) skin reaction evoked by tuberculin purified protein derivative (PPD) in guinea pigs receiving BCG intravesically appeared slightly earlier in animals pretreated intravesically with MMC than in phosphatebuffered saline (PBS)-pretreated animals. However, after completing BCG instillations no differences in DTH reaction were observed between these treatment groups. The extent of the local inflammatory reaction in the bladder wall, as well as the parameters measured in the draining iliacal lymph nodes (i.e., the weight, the number of leukocytes, and the composition of leukocyte, subpopulations), did not differ in animals treated with GCG alone or in combination with MMC. A slight increase in the MHC class II expression on the bladeer urothelium was shown if MMC and BCG treatment was combined. The adherence of mycobacteria to the bladder wall, measured using 3H-labeled mycobacteria, dit not differ between MMC/BCG-and BCG-treated animals. We conclude that MMC does not enhance the immune response against mycobacteria. Therefore, we hypothesize that a possible increased antitumor activity by the combination of MMC and BCG might be due to separate, rather than synergistic, effects of the drugs, namely a cytostatic effect of MMC on tumor cells and a local immune response in the bladder evoked by BCG.

Key words

Mitomycin C Bacillus Calmette-Guérin Superficial bladder cancer Guinea pig 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Badalament RA, Herr HW, Wong GY, Genecco C, Pinsky CM, Whitmore WF, Fair WR, Oetggen HF (1987) A prospective randomized trial of maintenance versus non-maintenance intravesical Bacillus calmette-Guérin therapy of superficial bladder cancer. J Clin Oncol 5:441Google Scholar
  2. 2.
    Badalament RA, Franklin GL, Page CM, Dasani BM, Wientjes MG, Drago JR (1992) Enhancement of bacillus Calmette-Guérin attachment to the urothelium by removal of the rabbit bladder mucin layer. J Urol 147:482Google Scholar
  3. 3.
    Bracken B, Johnson D, Von Eschenbach A, Swanson D, De Furia D, Crook S (1980) Role of intravesical mitomycin in management of superficial bladder tumors. Urology 16:11Google Scholar
  4. 4.
    Brosman SA, Lamm DL, Van Der Meijden APM, Debruyne FMJ (1989) A practical guide to the use of intravesical BCG for the management of stage Ta, T1, CIS, transitional cell cancer. In: Debruyne FMJ, Denis L, Van der Meijden APM (eds) EORTC Genito-Urinary Monograph 6: BCG in superfical bladder cancer. Alan R. Liss, New York, p 311Google Scholar
  5. 5.
    Catalona WJ, Hudson MA, Gillen DP, Andriole GL, Ratliff TL (1987) Risk and benefits of repeated courses of intravesical Bacillus Calmette-Guérin therapy for superficial bladder cancer. J Urol 137:220Google Scholar
  6. 6.
    Claesser AME, Bloemena E, Bril H, Meijer CJ, Scheper RJ (1992) Locoregional administration of etoposide, but not of interleukin-2, facilitates active specific immunization in guinea pigs with advanced carcinoma. Cancer Res 52:2440Google Scholar
  7. 7.
    Debruyne FMJ, Van der Meijden APM, Geboers ADH, Franssen MPH, Van Leeuwen MJW, Steerenberg PA, De Jong WH, Ruitenberg EJ (1988) BCG (RIVM) versus mitomycin intraves cal therapy in superficial bladder cancer. First results of randomized prospective trial. Suppl Urology 31:20Google Scholar
  8. 8.
    De Jager R, Guinan P, Lamm D, Khanna O, Brosman S, De Kernion J, Williams R, Richardson BA, Muenz L, Reitsma D, Hanna MG (1991) Long-term complete remission in bladder carcinorna in situ with intravesical Tice Bacillus Calmette-Guérin. Overview analysis of six phase II clinical trials. Urology 38:507Google Scholar
  9. 9.
    De Jong WH, De Boer EC, Van der Meijden APM, Steerenberg PA, Debruyne FMJ (1991) Intravesical BCG administration in the guinea pig. II Immunohistochemical characterization of cellular infiltrate after one or two cycles of intravesical BCG. Virchows Arch [Cell Pathol] 61:159Google Scholar
  10. 10.
    Friedman D, Mooppan UMM, Rosen Y, Kim H (1991) The effect of intravesical instillations of thiotepa, mitomycin C, and adriamycin on normal bladder urothelium: an experimental study in rats. J Urol 145:1060Google Scholar
  11. 11.
    Heney NM, Koontz WW, Barton B, Soloway M, Trump DL, Hazra T, Weinstein RS (1988) Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and Tis transitional cell carcinoma of the bladder. A phase III prospective randomized study. J Urol 140:1390Google Scholar
  12. 12.
    Hudson MA, Ritchey JK, Catalona WJ, Brown EJ, Ratliff TL (1990) Comparison of the fibronectin-binding ability and anti-tumor efficacy of various Mycobacteria. Cancer Res 50:3843Google Scholar
  13. 13.
    Hudson MA, Yuan JJ, Catalona WJ, Rarliff TL (1990) Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer. J Urol 144:1362Google Scholar
  14. 14.
    Huland E, Huland H (1989) Local continuous high dose Interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res 49:5469Google Scholar
  15. 15.
    Huland H, Otto U, Droese M, Kloeppel G (1984) Longterm mitomycin C instillation after resection of superficial ladder carcinoma: influence on recurrence, progression, and survival. J Urol 132:27Google Scholar
  16. 16.
    Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL (1990) Fibronectin-mediated Calmette-Guérin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor responsc. J Clin Invest 85:62Google Scholar
  17. 17.
    Koontz WW, Heney NM, Soloway MS, Kluskens L, Hazra TA, Trump DL, Barton B (1985) Mitomycin C for patients who have failed on thiotepa. Urology 26:30Google Scholar
  18. 18.
    Kurth KH, Maksimovic PA, Hop WCJ, Schröder FH, Bakker NJ (1983) Single-dose intravesical epodyl after TUR of Ta transiticnal cell bladder carcinoma. World J Urol 1:89Google Scholar
  19. 19.
    Kurth KH, Schroeder FH, Tunn U, Ay R, Pavone-Macaluso M, Debruyne F, De Pauw M, Dalesio O, Ten Kate F (1984) Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of an European Organization for research on treatment of cancer. Randomized trial comparing doxorubicin hydrocloride, ethoglucid and transurethral resection alone. J Urol 132:258Google Scholar
  20. 20.
    Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA, Sullivan J, Sarosdy MF, Crissman JA, Coltman CA (1991) A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med 325:1205Google Scholar
  21. 21.
    Limpens J, Garssen J, Germeraad WThV, Scheper RJ (1990) Enhancing effects of locally administered cytostatic drugs on T effector cell functions in mice. Int J Immunopharmacol 12:77Google Scholar
  22. 22.
    Martinez-Pineiro JA, Jimenez León J, Martinez-PineiroJr, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P (1989) Intravesical therapy comparing BCG, Adriamycin and Thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study. In: Debruyne FMJ, Denis L, Van Der Meijden APM (eds) EORTC Genito-Urinary Group Monograph 6: BCG in superficial bladder cancer. Liss, New York, p 237Google Scholar
  23. 23.
    Prescott S, James K, Busuttil A, Hargreave TB, Chisholm GD, Smyth JF (1989) HLA-DR expression by high grade superficial bladder cancer treated with BCG. Br J Urol 63:264Google Scholar
  24. 24.
    Ratliff TL, Palmer JO, McGarr JA, Brown EJ (1987) Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin. Cancer Res 47:1762Google Scholar
  25. 25.
    Soloway MS, Ford KS (1983) Subsequent tumor analysis of 36 patients who have received intravesical mitomycin-C for superficial bladder cancer. J Urol 130:74Google Scholar
  26. 26.
    Steerenberg PA, De Jong WH, Elgersma A, Burger R; Poels LG, Claessen AME, Den Otter W, Ruitenberg EJ (1990) Tumor infiltrating leukocytes (tils) during progressive tumor growth and BCG-mediated tumor regression. Virchows Arch [Cell Pathol] 59:185Google Scholar
  27. 27.
    Steerenber PA, De Jong WH, Geerse E, De Graaf A, Scheper RJ, Den Otter W, Ruitenberg EJ (1991) MHC class II antigen expression on leukocyte subpopulations in the draining lymph node and tumor in the early phase of BCG induced regression. Cancer Immunol Immunother 33:189Google Scholar
  28. 28.
    Tan BTG; Limpens J, Koken M, Valster H, Scheper RJ (1986) Local administration of various cytostatic drugs after subcutaneous immunization enhanced type hypersensitivity reaction to sheep red blood cells in mice. Scan J Immunol 23:605Google Scholar
  29. 29.
    Teppema JS, De Boer EC, Steerenberg PA, Van Der Meijden APM (1992) Morphological aspects of the interaction of Bacillus Calmette-Guérin with urothelial bladder cells in vivo and in vitro: relevance for antitumor activity? Urol Res 20:219Google Scholar
  30. 30.
    Van Der Meijden APM, De Jong WH, Steerenberg PA, Walvoort HC, De Boer EC, Debruyne FMJ, Ruitenberg E (1988) Intravesical BCG administration in the guinea pig. A histomorphological study. Virchows Arch [Cell Pathol] 55:207Google Scholar
  31. 31.
    Van Der Meijden APM, De Jong WH, De Boer EC, Steerenberg PA, Debruyne FMJ, Ruitenberg EJ (1989) Immunological aspects of intravesical administration of bacillus Calmette-Guérin (BCG) in the guinea pig. Urol Res 17:47Google Scholar
  32. 32.
    Wientjes MG, Dalton JT, Badalament RA, Drago JR, Au JL (1991) Baldder wall penetration of intravesical mitomycin C in dogs. Cancer Res 51:4347Google Scholar
  33. 33.
    Witjes JA, Van Der Meijden APM, Debruyne FMJ (1990) Use of intravesical Bacillus Calmette-Guérin in the treatment of superfical transitional cell carcinoma of the bladder: an overview. Urol Int 45:129Google Scholar
  34. 34.
    Zincke H, Utz DL, Taylor WF, Myers RP, Leary FJ (1983) Influence of thiotepa and doxorubicin at time of transurethral surgical treatment of bladder cancer in tumor recurrence: a prospective, randomized, controlled trial. J Urol 129:505Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • L. T. M. Balemans
    • 1
    • 2
  • P. D. J. Vegt
    • 3
  • P. A. Steerenberg
    • 1
  • E. C. De Boer
    • 1
  • A. Van Swaaij
    • 1
  • R. E. M. De Vries
    • 1
  • A. P. M. Van Der Meijden
    • 4
  • W. Den Otter
    • 1
    • 2
  1. 1.Laboratory for PathologyNational Institute of Public Health and Environmental Protection (NIPHEP)BilthovenThe Netherlands
  2. 2.Department of PathologyUniversity HospitalUtrechtThe Netherlands
  3. 3.Department of Urology, St.Elisabeth HospitalLeiderdorpThe Netherlands
  4. 4.Department of UrologyGroot-Ziekengasthuis's-HertogenboschThe Netherlands

Personalised recommendations